BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

196 related articles for article (PubMed ID: 25883396)

  • 1. Competing for public funding of medicines to treat rare disorders in New Zealand.
    Crausaz S
    Bull World Health Organ; 2015 Feb; 93(2):67. PubMed ID: 25883396
    [No Abstract]   [Full Text] [Related]  

  • 2. Medicines for rare (orphan) diseases: an enquiry and proposal for tax-incentives.
    John JE
    Drug Discov Today; 2011 Dec; 16(23-24):999-1000. PubMed ID: 22020052
    [No Abstract]   [Full Text] [Related]  

  • 3. [Conference 1. An economic observatory for orphan drugs: myth or reality?].
    Duguet C; Ferry A
    Med Sci (Paris); 2014 Apr; 30 Spe(1):21-3. PubMed ID: 24755173
    [No Abstract]   [Full Text] [Related]  

  • 4. The European rare diseases therapeutic initiative.
    Fischer A; Borensztein P; Roussel C
    PLoS Med; 2005 Sep; 2(9):e243. PubMed ID: 16104832
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [European incentives for orphan medicinal products].
    Enzmann H; Lütz J
    Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz; 2008 May; 51(5):500-8. PubMed ID: 18696141
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Authorization and reimbursement of orphan drugs in an international comparison].
    Roll K; Stargardt T; Schreyögg J
    Gesundheitswesen; 2011 Aug; 73(8-9):504-14. PubMed ID: 20848380
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Limits on use of health economic assessments for rare diseases.
    Hyry HI; Stern AD; Cox TM; Roos JC
    QJM; 2014 Mar; 107(3):241-5. PubMed ID: 24453281
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Companies look for profit in orphan drugs.
    Thompson CA
    Am J Health Syst Pharm; 2010 Nov; 67(22):1892, 1895-6. PubMed ID: 21048203
    [No Abstract]   [Full Text] [Related]  

  • 9. Regulatory approval and public drug plan listing of new drugs for rare disorders in Canada and New Zealand.
    Rawson NSB
    J Popul Ther Clin Pharmacol; 2020 Jun; 27(2):e58-e67. PubMed ID: 32543163
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Rare diseases and effective treatments: are we delivering?
    Luzzatto L; Hollak CE; Cox TM; Schieppati A; Licht C; Kääriäinen H; Merlini G; Schaefer F; Simoens S; Pani L; Garattini S; Remuzzi G
    Lancet; 2015 Feb; 385(9970):750-2. PubMed ID: 25752159
    [No Abstract]   [Full Text] [Related]  

  • 11. New drugs carry hefty price tags. Makers of leading-edge orphan products asked to cut prices, take smaller profits.
    Lee J
    Mod Healthc; 2013 Oct; 43(40):14. PubMed ID: 24340725
    [No Abstract]   [Full Text] [Related]  

  • 12. Pfizer explores rare disease path.
    Shaffer C
    Nat Biotechnol; 2010 Sep; 28(9):881-2. PubMed ID: 20829809
    [No Abstract]   [Full Text] [Related]  

  • 13. Review of regulatory recommendations for orphan drug submissions in the Netherlands and Scotland: focus on the underlying pharmacoeconomic evaluations.
    Vegter S; Rozenbaum MH; Postema R; Tolley K; Postma MJ
    Clin Ther; 2010 Aug; 32(9):1651-61. PubMed ID: 20974323
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Regulators adopt more orphan drugs.
    Reardon S
    Nature; 2014 Apr; 508(7494):16-7. PubMed ID: 24695293
    [No Abstract]   [Full Text] [Related]  

  • 15. Are rare diseases still orphans or happily adopted? The challenges of developing and using orphan medicinal products.
    Dear JW; Lilitkarntakul P; Webb DJ
    Br J Clin Pharmacol; 2006 Sep; 62(3):264-71. PubMed ID: 16934041
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A new era of hope for the world's most neglected diseases.
    The
    PLoS Med; 2005 Sep; 2(9):e323. PubMed ID: 16138790
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The challenges of orphan drugs and orphan diseases: real and imagined.
    Hudson I; Breckenridge A
    Clin Pharmacol Ther; 2012 Aug; 92(2):151-3. PubMed ID: 22814659
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Rationing of drugs for rare diseases.
    Hughes D
    Pharmacoeconomics; 2006; 24(4):315-6. PubMed ID: 16605277
    [No Abstract]   [Full Text] [Related]  

  • 19. Reducing the cost of rare disease drugs.
    Lancet; 2015 Feb; 385(9970):746. PubMed ID: 25752156
    [No Abstract]   [Full Text] [Related]  

  • 20. A discrete choice experiment investigating preferences for funding drugs used to treat orphan diseases: an exploratory study.
    Mentzakis E; Stefanowska P; Hurley J
    Health Econ Policy Law; 2011 Jul; 6(3):405-33. PubMed ID: 21205401
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.